Psyllium in Pediatric IBS (Psyllium)
Assessing Psyllium Given With Meals for Fructan Sensitivity in Children With Irritable Bowel Syndrome
The goal of this clinical trial is to learn if a fiber (psyllium) can change the way bacteria use fructans (a type of sugar) and whether psyllium can help decrease childhood irritable bowel syndrome (IBS) symptoms when eating fructans. The main questions it aims to answer are:
Aim 1: The effect of psyllium at two doses given with a fructan meal on microbial fructan fermentation (intracolonic pH; H2 gas production; gut microbiome composition; fecal short-chain fatty acids, lactate, glycomics).
Aim 2: Determine the impact of psyllium given with a fructan meal on fructan-induced GI symptoms.
Participants will first be asked to eat a specific diet over two three-day periods to determine if fructans worsen their IBS symptoms. Those with worsening symptoms with fructans will be asked to participate in the second part of the study. This includes two weeks of baseline (no change in diet) and two weeks of eating a specific diet with fructans with either psyllium or glucose. Participants will be asked to complete pain and stool diaries, submit stool specimens, swallow a pill to capture gut acid levels, and give breath samples.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Annette Babu
- Phone Number: 919-660-1227
- Email: annette.babu@duke.edu
Study Contact Backup
- Name: Bruno Chumpitazi, MD, MPH
- Phone Number: 919-660-1227
- Email: bruno.chumpitazi@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University
-
Contact:
- Annette Babu
- Phone Number: 9196601227
- Email: annette.babu@duke.edu
-
Principal Investigator:
- Bruno Chumpitazi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Children between the ages of 12-17 years meeting pediatric Rome IV criteria for IBS
Exclusion Criteria:
- Children who have had previous bowel surgery, have documented GI disorders (e.g., ulcerative colitis), or a serious chronic medical condition (e.g., diabetes)
- weight and/or height are > or < 2 SD for age
- have chronic conditions with GI symptoms (e.g., cystic fibrosis)
- have been on antibiotics or probiotics within 3 months (because of potential alterations to the GI microbiome0
- girls who are pregnant (tested with urine beta-human chorionic gonadotropin at the initial visit)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Psyllium (0.7 g/year of age per day) given with fructans
Participants will receive Psyllium (0.7 g/year of age per day) given with fructans (daily dose 0.5 g/kg up to 19 grams)
|
Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
|
|
Active Comparator: Psyllium (0.5 g/year of age per day) given with fructans
Participants will receive Psyllium (0.5 g/year of age per day) given with fructans (daily dose 0.5 g/kg up to 19 grams)
|
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
|
|
Placebo Comparator: Placebo (0.7 g/year of age glucose) given with fructans
Participants will receive Placebo (0.7 g/year of age glucose) given with fructans (daily dose 0.5 g/kg up to 19 grams).
|
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate & Lyle, Staley, London, UK)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in microbiome composition measured via taxonomic profiling using 16S ribosomal RNA gene amplicon sequencing
Time Frame: Baseline, 2 weeks
|
Baseline, 2 weeks
|
|
Change in fecal lactate
Time Frame: Baseline, 2 weeks
|
Baseline, 2 weeks
|
|
Change in fecal short-chain fatty acids
Time Frame: Baseline, 2 weeks
|
Baseline, 2 weeks
|
|
Change in hydrogen gas production
Time Frame: Baseline, 2 weeks
|
Baseline, 2 weeks
|
|
Change in fecal fructans
Time Frame: Baseline, 2 weeks
|
Baseline, 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in abdominal pain frequency
Time Frame: Baseline, 2 weeks
|
Baseline, 2 weeks
|
|
|
Change in abdominal pain severity
Time Frame: Baseline, 2 weeks
|
Participants will rate abdominal pain on a scale of 0-10, with higher scores indicating more severe pain.
|
Baseline, 2 weeks
|
|
Change in bloating severity
Time Frame: Baseline, 2 weeks
|
Participants will rate bloating on a scale of 0-10, with higher scores indicating worse bloating.
|
Baseline, 2 weeks
|
|
Change in flatulence severity
Time Frame: Baseline, 2 weeks
|
Participants will rate flatulence on a scale of 0-10, with higher scores indicating worse flatulence.
|
Baseline, 2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Bruno Chumpitazi, MD, MPH, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Signs and Symptoms, Digestive
- Intestinal Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Colonic Diseases, Functional
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Irritable Bowel Syndrome
- Abdominal Pain
- Carbohydrates
- Polysaccharides
- Plant Extracts
- Plant Preparations
- Biological Products
- Complex Mixtures
- Psyllium
- Fructans
Other Study ID Numbers
Other Study ID Numbers
- Pro00114630
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.